Study of vorolanib tablets in people with liver problems
This study looks at how the body handles the study drug vorolanib (taken as a tablet) when your liver is impaired. It might help doctors understand the right dose for people with liver problems, and it may also benefit those who are newly diagnosed or exploring treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have either normal liver function with matching age, weight, and sex to the liver-impaired group, or you must have mild to moderate liver problems (Child-Pugh A or B) and cirrhosis.
- You must not have severe liver complications such as acute liver injury, a previous liver transplant, liver failure, or active bleeding in the esophagus or stomach.
- Your lab results must meet certain safety limits (e.g., blood counts, liver enzymes, and tumor marker levels).
- You must agree to use effective birth control and not donate sperm or eggs for 6 months after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how the drug vorasidenib behaves in people with severe liver problems compared to healthy volunteers. It helps doctors understand if the drug needs different dosing for patients with liver disease.
This study checks how the experimental cancer drug vorolanib interacts with other medicines when taken together. It is for healthy people to help find the right dose and safety information before it is tested in patients.
This trial tests a targeted therapy pill called Vorolanib for people with advanced non-small cell lung cancer who have already tried at least two other treatments. It aims to see if the drug can help shrink or control the cancer.
This trial tests a targeted therapy pill, vorolanib, for people with advanced kidney cancer that has clear cell features and has gotten worse after initial treatment. It may offer a new option when standard second-line treatments are not working.
This trial tests how a drug called olverembatinib is processed by the body in people with different levels of liver impairment. It looks at how the liver condition affects the drug levels and safety, which may help find the right dose.
This study looks at how a new oral drug (called INCB161734) is processed by the body and how safe it is in people with liver problems. It may help doctors understand the right dose for patients with liver impairment.
Hear when a new Hepatic Impairment (HI) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.